Open company graph database — free web & API
Login

Noir Immune BioTech Inc.

ノイルイミューン・バイオテック株式会社Noile-Immune Biotech Inc.Alias
Ticker
Listed market
TYO
Country
Japan
Employees (consolidated)
23
Related companies
12
§01

Basic information

BASIC
Head office
5F, T&G Hamamatsucho Building, 12-10, 2-chome, Shiba, Minato-ku, Tokyo
Chief executive
Koji Tamada
Capital
4,047 JPY
Employees (non-consolidated)
25 people
Employees (consolidated)
23 people
Start date
2015-04-16
End date
§02

Websites

1 DOMAINS
§03

Business

1
Development of novel cancer immunotherapies primarily focused on CAR-T cell therapy
§04

Related companies

12 COMPANIES
Company name Group Parent Subsidiary Customer Supplier Alliance Bank Shareholder
Takara Bio Inc.
Group
山口大学
Group Alliance
Hitachi Ltd.
Group
Chugai Pharmaceutical Co., Ltd.
Group
Adaptimmune Limited
Group
Autolus Limited
Group
Millennium Pharmaceuticals, Inc.
Group
NIB_partner
Group
インターフェックス
Group
Takeda Pharmaceutical Company, Limited
Group
Kyushu University
Alliance
University of Tokyo
Alliance
Names without a link are companies not yet registered in OpenBizGraph
§05

Network

NETWORK
Drag to move · click to open
§06

History

23 EVENTS

Established as a venture company originating from the National Cancer Center (hereinafter referred to as the National Cancer Center) and Yamaguchi University (hereinafter referred to as Yamaguchi University) in Chuo-ku, Tokyo.Sources

Established as a venture company originating from the National Cancer Center and Yamaguchi University in Chuo-ku, Tokyo.Sources

Date of establishment: April 16, 2015.Sources

EstablishmentSources

Entered into a joint research agreement with Yamaguchi University.Sources

Obtained exclusive implementation license with sublicense rights to third parties for next-generation CAR-T cell platform technology from Yamaguchi University.Sources

Partnered with Takeda Pharmaceutical Company (hereinafter referred to as Takeda Pharmaceutical) for joint research and development.Sources

Partnered with Takeda Pharmaceutical Company for joint research and development.Sources

Signed a license agreement with Takeda Pharmaceutical regarding the derivation of NIB102 and NIB103. (※2)Sources

Signed a license agreement with Takeda Pharmaceutical regarding the derivation of NIB102 and NIB103.Sources

Relocated headquarters to Minato-ku, Tokyo.Sources

Signed a joint development agreement with Adaptimmune Therapeutics plc. (※3)Sources

Signed a joint development agreement with Adaptimmune Therapeutics plc.Sources

Signed a license agreement with Autolus Therapeutics plc. (※4)Sources

Signed a licensing agreement with Autolus Therapeutics plc.Sources

Takeda Pharmaceutical commenced Phase I clinical trials of NIB102.Sources

Takeda Pharmaceutical commenced Phase I clinical trials of NIB103.Sources

Commenced Phase I clinical trials of in-house pipeline NIB101.Sources

Signed a license agreement with Chugai Pharmaceutical Co., Ltd.Sources

Listed on the Tokyo Stock Exchange Growth Market.Sources

Entered into a business partnership agreement for joint development with Takara Bio Inc. (※5, ※6).Sources

Signed a business partnership agreement for joint development with Takara Bio Inc.Sources

Completed submission of the clinical trial plan for Phase I trials of NIB103.Sources

§07

News

0 ARTICLES

There is no news.

§08

Public records

GOV
National Tax Agency basic information1010001167340
Source: National Tax Agency Corporate Number Publication Site, basic three itemsSources
Trade name
ノイルイミューン・バイオテック株式会社
Trade name (kana)
ノイルイミューンバイオテック
Name in English
Corporation type
301
Address
〒105-0012 東京都港区芝大門2丁目12番10号
Postal code
1050012
Prefecture code
13
City code
103
Address outside Japan
Prefecture in English
City in English
Address outside Japan in English
Corporate number assignment date
2015-10-05
Update date
2019-04-19
Change date
2019-04-15
Registry closure date
Reason for registry closure
Successor corporate number
Details of the change
Latest record
1
Excluded from search
0
Processing type
12
Correction type
0
Trade name image ID
Address image ID
Sequence number
1278930
METI gBizINFO1010001167340
Source: gBizINFO (Ministry of Economy, Trade and Industry)Sources
Corporate number
1010001167340
Trade name
ノイルイミューン・バイオテック株式会社
Trade name (kana)
ノイルイミューンバイオテック
Trade name (alphabet)
Registry closure date
Reason for registry closure
Registered address
東京都港区芝大門2丁目12番10号
Postal code
1050012
Prefecture
東京都
Prefecture code
13
City or district
港区
City code
103
Street address
芝大門2丁目12番10号
Organisation type
301
Processing type
12
Correction type
0
Status
Representative
代表取締役社長 玉田 耕治
Capital
4047254000
Employees
23
Employees (male)
Employees (female)
Business summary
Website URL
Year founded
Business category
Date established
Unified government qualification - grade
Unified government qualification - business items
Update date
2019-04-19
Key information
1010001167340
§09

Sources & updates

SOURCES
↑